EPHA2 and cancer: Recent studies have shown that Epha2-SE deletion leads to decreased EphA2 expression, which inhibits Wnt/β-catenin and PI3K/AKT pathway activation, thereby inhibiting the invasion and migration of cancer cells, including MCF-7 cells, HCT-116 cells, and HeLa cells [143].